SCHEMBL8294499

SCHEMBL8294499

Cc1cnc(NCCN2CCOCC2)c(=O)n1CCNCCc1cccc(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.49
F2 P00734 2/20 0.46
MAPK1 P28482 1/20 0.44
FLT3 P36888 1/20 0.44
LMNA P02545 4/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPT P10636 1/20 0.43
PRSS1 P07477 1/20 0.42
TP53 P04637 1/20 0.42
ACHE P22303 1/20 0.42
PDE1A P54750 2/20 0.41
PDE1B Q01064 2/20 0.41
PDE1C Q14123 2/20 0.41
SIGMAR1 Q99720 1/20 0.41
MAPK8 P45983 1/20 0.40
CYP1A2 P05177 2/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2D6 P10635 2/20 0.40
HIF1A Q16665 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8293952 0.93 SMN1; SMN2 (0.51) SMN1; SMN2F2MAPK1FLT3LMNA
SCHEMBL8292996 0.91 F2 (0.47) SMN1; SMN2F2PRSS1ACHESIGMAR1
SCHEMBL8292998 0.84 F2 (0.51) SMN1; SMN2F2FLT3PRSS1ACHE
SCHEMBL8294072 0.81 F2 (0.55) F2PRSS1
SCHEMBL8292311 0.80 F2 (0.59) F2PRSS1CYP2D6
SCHEMBL8293024 0.80 F2 (0.49) F2PRSS1
SCHEMBL8293839 0.79 F2 (0.53) F2PRSS1
SCHEMBL8293955 0.79 F2 (0.53) F2PRSS1
SCHEMBL5475414 0.77 MAOA (0.42) SMN1; SMN2F2MEN1KMT2APRSS1
SCHEMBL5479118 0.76 CYP3A4 (0.45) SMN1; SMN2MAPK1LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070099927-A1 Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2007-05-03 US disclosed
US-20070099927-A1 Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2007-05-03 US disclosed
WO-2005040137-A1 AMINOALKYL-PYRAZINONES AND -PYRIDONES AS THROMBIN INHIBITORS SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099927-A1 Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors F2, F12, SERPINC1 SMN1; SMN2 4873/4885F2 1/4885MAPK1 2125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.